25 June 2015 
EMA/CHMP/420571/2015  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Voncento 
human coagulation factor VIII / human von Willebrand factor 
On 25 June 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Voncento. The marketing authorisation holder for this medicinal product is CSL Behring GmbH. 
The CHMP adopted an extension to an existing indication as follows2:  
“Prophylaxis and tTreatment of haemorrhage or prevention and treatment of surgical bleeding in 
patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.” 
For information, the full indications for Voncento will be as follows: 
“von Willebrand disease (VWD) 
Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin 
(DDAVP) treatment alone is ineffective or contraindicated. 
Haemophilia A (congenital FVIII deficiency) 
Prophylaxis and treatment of bleeding in patients with haemophilia A.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
  
 
 
 
  
                                                
